S-1: Microbot Medical Files for Resale of 1,005,965 Shares Following Settlement

Microbot Medical is registering the resale of 1,005,965 shares of its common stock by selling stockholders following a settlement agreement.

Summary

• Microbot Medical has filed a registration statement for the resale of up to 1,005,965 shares of its common stock.
• These shares were issued as part of a settlement agreement with Empery Asset Master Ltd., Empery Tax Efficient, LP, Empery Tax Efficient III, LP and Hudson Bay Master Fund Ltd. to resolve a lawsuit.
• The lawsuit involved allegations of breached representations and warranties related to a June 8, 2017 equity financing.
• Microbot paid $2,154,000 to settle the lawsuit, including a cash payment of $1,100,000 and the issuance of 1,005,965 restricted common stock.
• The selling stockholders may sell the shares from time to time.
• Microbot will not receive any proceeds from the sale of these shares.
• The company's common stock is listed on the Nasdaq Capital Market under the ticker symbol MBOT.
• On February 16, 2024, the last reported closing price of Microbot's common stock was $1.29.

Sentiment

Score: 4

Explanation: The document is largely neutral, focusing on the details of the share resale and settlement. The mention of ongoing risks in Israel and the company's need for additional funding contribute to a slightly negative sentiment.

Positives

• The settlement resolves a legal dispute, removing uncertainty and potential financial risk.
• The cash portion of the settlement was covered by insurance, minimizing the direct financial impact on Microbot.
• The company is moving forward with its clinical trial in humans, having submitted an Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration.

Negatives

• The company will not receive any proceeds from the resale of the 1,005,965 shares.
• The issuance of 1,005,965 shares will cause dilution to existing shareholders.
• The company has a limited operating history outside of being a research and development-stage company, which may make it difficult to evaluate the prospects for the Company's future viability.
• The company has a limited operating history outside of being a research and development-stage company, which may make it difficult to evaluate the prospects for the Company's future viability.

Risks

• The company has a limited operating history outside of being a research and development-stage company, which may make it difficult to evaluate the prospects for the Company's future viability.
• The company will need additional funding and if it is unable to raise capital when needed, it could be forced to delay, reduce or eliminate its product development programs or commercialization efforts.
• The company's business depends heavily on the success of its sole lead product candidate, the LIBERTY Endovascular Robotic Surgical System.
• The company's operations in Israel are being exacerbated by the current military actions and operations, and related activities, that commenced with the surprise attack on the State of Israel on October 7, 2023.

Future Outlook

The company expects to continue incurring losses for the foreseeable future as it continues the development of, and seeks regulatory review of, its product candidates, and begins to commercialize any approved or cleared products following a successful regulatory review.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors beyond mentioning the competitive landscape for the LIBERTY Endovascular Robotic Surgical System.

Legal Proceedings

• The document details the settlement of a lawsuit with Empery Asset Master Ltd., et al., involving allegations of breached representations and warranties related to a 2017 equity financing.

Stakeholder Impact

• The resale of shares may impact the share price, affecting current shareholders.
• The company's ability to secure additional funding will impact its ability to continue development of the LIBERTY Endovascular Robotic Surgical System, affecting future prospects for employees and investors.

Next Steps

• The selling stockholders may sell or otherwise dispose of the shares of common stock covered by this prospectus in a number of different ways and at varying prices.
• The company will continue to seek new sources of capital to stabilize its finances and provide operating runway subsequent to June 2024.
• The company will commence audits for ISO 13485 certification to ensure compliance with the Quality Management System (QMS) requirements of the EU Medical Devices Regulation (MDR 2017/745), during the first half of 2024.

Key Dates

Keywords

resale, common stock, settlement, LIBERTY Endovascular Robotic Surgical System, shares, Microbot Medical, financing